CovidChloroV1, Main, Exploration, bibRecord, 000B49

The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.

Identifieur interne : 000B49 ( Main/Exploration ); précédent : 000B48; suivant : 000B50

The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.

Auteurs : Jung-Hyun Won [Corée du Sud] ; Howard Lee [Corée du Sud]

Source :

International journal of molecular sciences [ 1422-0067 ] ; 2020.

RBID : pubmed:33371468

Descripteurs français

KwdFr :
- Antipaludiques (usage thérapeutique), Antiviraux (usage thérapeutique), Chloroquine (usage thérapeutique), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Inhibiteurs de protéases (usage thérapeutique), Nucléosides (analogues et dérivés), Nucléosides (usage thérapeutique), Pandémies (prévention et contrôle), Repositionnement des médicaments (MeSH), Santé publique (MeSH).
MESH :
- analogues et dérivés : Nucléosides.
- prévention et contrôle : Pandémies.
- usage thérapeutique : Antipaludiques, Antiviraux, Chloroquine, Hydroxychloroquine, Inhibiteurs de protéases, Nucléosides.
- Humains, Repositionnement des médicaments, Santé publique.

English descriptors

KwdEn :
- Antimalarials (therapeutic use), Antiviral Agents (therapeutic use), COVID-19 (drug therapy), COVID-19 (prevention & control), COVID-19 Vaccines (therapeutic use), Chloroquine (therapeutic use), Drug Repositioning (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Nucleosides (analogs & derivatives), Nucleosides (therapeutic use), Pandemics (prevention & control), Protease Inhibitors (therapeutic use), Public Health (MeSH), SARS-CoV-2 (drug effects), SARS-CoV-2 (physiology).
MESH :
- chemical , analogs & derivatives : Nucleosides.
- chemical , therapeutic use : Antimalarials, Antiviral Agents, COVID-19 Vaccines, Chloroquine, Hydroxychloroquine, Nucleosides, Protease Inhibitors.
- drug effects : SARS-CoV-2.
- drug therapy : COVID-19.
- physiology : SARS-CoV-2.
- prevention & control : COVID-19, Pandemics.
- Drug Repositioning, Humans, Public Health.

Abstract

Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed. Few of the repositioned drugs for COVID-19 have shown that they were efficacious and safe. In contrast, a couple of vaccines against SARS-CoV-2 will be ready for mass rollout early next year. Despite successful vaccine development for COVID-19, the world will face a whole new set of challenges including scale-up manufacturing, cold-chain logistics, long-term safety, and low vaccine acceptance. We highlighted the importance of knowledge sharing and collaboration to find innovative answers to these challenges and to prepare for newly emerging viruses.

DOI: 10.3390/ijms21249775
PubMed: 33371468
PubMed Central: PMC7767501

Affiliations:

Links toward previous steps (curation, corpus...)

to stream Main, to step Corpus: 000589
to stream Main, to step Curation: 000589

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.</title>
<author><name sortKey="Won, Jung Hyun" sort="Won, Jung Hyun" uniqKey="Won J" first="Jung-Hyun" last="Won">Jung-Hyun Won</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, Howard" sort="Lee, Howard" uniqKey="Lee H" first="Howard" last="Lee">Howard Lee</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 16229, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 16229</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2020">2020</date>
<idno type="RBID">pubmed:33371468</idno>
<idno type="pmid">33371468</idno>
<idno type="doi">10.3390/ijms21249775</idno>
<idno type="pmc">PMC7767501</idno>
<idno type="wicri:Area/Main/Corpus">000589</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000589</idno>
<idno type="wicri:Area/Main/Curation">000589</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000589</idno>
<idno type="wicri:Area/Main/Exploration">000589</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.</title>
<author><name sortKey="Won, Jung Hyun" sort="Won, Jung Hyun" uniqKey="Won J" first="Jung-Hyun" last="Won">Jung-Hyun Won</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Lee, Howard" sort="Lee, Howard" uniqKey="Lee H" first="Howard" last="Lee">Howard Lee</name>
<affiliation wicri:level="4"><nlm:affiliation>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
<affiliation wicri:level="1"><nlm:affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul 03080, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul 03080</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
</affiliation>
<affiliation wicri:level="4"><nlm:affiliation>Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 16229, Korea.</nlm:affiliation>
<country xml:lang="fr">Corée du Sud</country>
<wicri:regionArea>Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 16229</wicri:regionArea>
<placeName><settlement type="city">Séoul</settlement>
<region type="capital">Région capitale de Séoul</region>
</placeName>
<orgName type="university">Université nationale de Séoul</orgName>
<placeName><settlement type="city">Séoul</settlement>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j">International journal of molecular sciences</title>
<idno type="eISSN">1422-0067</idno>
<imprint><date when="2020" type="published">2020</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antimalarials (therapeutic use)</term>
<term>Antiviral Agents (therapeutic use)</term>
<term>COVID-19 (drug therapy)</term>
<term>COVID-19 (prevention & control)</term>
<term>COVID-19 Vaccines (therapeutic use)</term>
<term>Chloroquine (therapeutic use)</term>
<term>Drug Repositioning (MeSH)</term>
<term>Humans (MeSH)</term>
<term>Hydroxychloroquine (therapeutic use)</term>
<term>Nucleosides (analogs & derivatives)</term>
<term>Nucleosides (therapeutic use)</term>
<term>Pandemics (prevention & control)</term>
<term>Protease Inhibitors (therapeutic use)</term>
<term>Public Health (MeSH)</term>
<term>SARS-CoV-2 (drug effects)</term>
<term>SARS-CoV-2 (physiology)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Antipaludiques (usage thérapeutique)</term>
<term>Antiviraux (usage thérapeutique)</term>
<term>Chloroquine (usage thérapeutique)</term>
<term>Humains (MeSH)</term>
<term>Hydroxychloroquine (usage thérapeutique)</term>
<term>Inhibiteurs de protéases (usage thérapeutique)</term>
<term>Nucléosides (analogues et dérivés)</term>
<term>Nucléosides (usage thérapeutique)</term>
<term>Pandémies (prévention et contrôle)</term>
<term>Repositionnement des médicaments (MeSH)</term>
<term>Santé publique (MeSH)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Nucleosides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antimalarials</term>
<term>Antiviral Agents</term>
<term>COVID-19 Vaccines</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Nucleosides</term>
<term>Protease Inhibitors</term>
</keywords>
<keywords scheme="MESH" qualifier="analogues et dérivés" xml:lang="fr"><term>Nucléosides</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>COVID-19</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS-CoV-2</term>
</keywords>
<keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>COVID-19</term>
<term>Pandemics</term>
</keywords>
<keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Pandémies</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antipaludiques</term>
<term>Antiviraux</term>
<term>Chloroquine</term>
<term>Hydroxychloroquine</term>
<term>Inhibiteurs de protéases</term>
<term>Nucléosides</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Drug Repositioning</term>
<term>Humans</term>
<term>Public Health</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Humains</term>
<term>Repositionnement des médicaments</term>
<term>Santé publique</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed. Few of the repositioned drugs for COVID-19 have shown that they were efficacious and safe. In contrast, a couple of vaccines against SARS-CoV-2 will be ready for mass rollout early next year. Despite successful vaccine development for COVID-19, the world will face a whole new set of challenges including scale-up manufacturing, cold-chain logistics, long-term safety, and low vaccine acceptance. We highlighted the importance of knowledge sharing and collaboration to find innovative answers to these challenges and to prepare for newly emerging viruses.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33371468</PMID>
<DateCompleted><Year>2021</Year>
<Month>01</Month>
<Day>05</Day>
</DateCompleted>
<DateRevised><Year>2021</Year>
<Month>01</Month>
<Day>05</Day>
</DateRevised>
<Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN>
<JournalIssue CitedMedium="Internet"><Volume>21</Volume>
<Issue>24</Issue>
<PubDate><Year>2020</Year>
<Month>Dec</Month>
<Day>21</Day>
</PubDate>
</JournalIssue>
<Title>International journal of molecular sciences</Title>
<ISOAbbreviation>Int J Mol Sci</ISOAbbreviation>
</Journal>
<ArticleTitle>The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.</ArticleTitle>
<ELocationID EIdType="pii" ValidYN="Y">E9775</ELocationID>
<ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms21249775</ELocationID>
<Abstract><AbstractText>Since the outbreak of coronavirus disease 2019 (COVID-19) was first identified, the world has vehemently worked to develop treatments and vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) at an unprecedented speed. Few of the repositioned drugs for COVID-19 have shown that they were efficacious and safe. In contrast, a couple of vaccines against SARS-CoV-2 will be ready for mass rollout early next year. Despite successful vaccine development for COVID-19, the world will face a whole new set of challenges including scale-up manufacturing, cold-chain logistics, long-term safety, and low vaccine acceptance. We highlighted the importance of knowledge sharing and collaboration to find innovative answers to these challenges and to prepare for newly emerging viruses.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Won</LastName>
<ForeName>Jung-Hyun</ForeName>
<Initials>JH</Initials>
<Identifier Source="ORCID">0000-0001-7335-8087</Identifier>
<AffiliationInfo><Affiliation>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Lee</LastName>
<ForeName>Howard</ForeName>
<Initials>H</Initials>
<Identifier Source="ORCID">0000-0001-6713-5418</Identifier>
<AffiliationInfo><Affiliation>Department of Molecular Medicine and Biopharmaceutical Sciences, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Center for Convergence Approaches in Drug Development, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 03080, Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, College of Medicine, Seoul National University, Seoul 03080, Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Clinical Pharmacology and Therapeutics, Seoul National University Hospital, Seoul 03080, Korea.</Affiliation>
</AffiliationInfo>
<AffiliationInfo><Affiliation>Department of Transdisciplinary Studies, Graduate School of Convergence Science and Technology, Seoul National University, Seoul 16229, Korea.</Affiliation>
</AffiliationInfo>
</Author>
</AuthorList>
<Language>eng</Language>
<GrantList CompleteYN="Y"><Grant><GrantID>5120200513755</GrantID>
<Agency>National Research Foundation of Korea (NRF)</Agency>
<Country></Country>
</Grant>
</GrantList>
<PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D016454">Review</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic"><Year>2020</Year>
<Month>12</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo><Country>Switzerland</Country>
<MedlineTA>Int J Mol Sci</MedlineTA>
<NlmUniqueID>101092791</NlmUniqueID>
<ISSNLinking>1422-0067</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000962">Antimalarials</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D009705">Nucleosides</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D011480">Protease Inhibitors</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber>
<NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>886U3H6UFF</RegistryNumber>
<NameOfSubstance UI="D002738">Chloroquine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000962" MajorTopicYN="N">Antimalarials</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
<QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002738" MajorTopicYN="N">Chloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058492" MajorTopicYN="Y">Drug Repositioning</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009705" MajorTopicYN="N">Nucleosides</DescriptorName>
<QualifierName UI="Q000031" MajorTopicYN="N">analogs & derivatives</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D058873" MajorTopicYN="N">Pandemics</DescriptorName>
<QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011480" MajorTopicYN="N">Protease Inhibitors</DescriptorName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011634" MajorTopicYN="N">Public Health</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
</MeshHeadingList>
<KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword>
<Keyword MajorTopicYN="N">SARS-CoV-2</Keyword>
<Keyword MajorTopicYN="N">drug repositioning</Keyword>
<Keyword MajorTopicYN="N">public health crisis</Keyword>
<Keyword MajorTopicYN="N">vaccine</Keyword>
</KeywordList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year>
<Month>11</Month>
<Day>30</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="revised"><Year>2020</Year>
<Month>12</Month>
<Day>15</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="accepted"><Year>2020</Year>
<Month>12</Month>
<Day>18</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2020</Year>
<Month>12</Month>
<Day>29</Day>
<Hour>1</Hour>
<Minute>4</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2020</Year>
<Month>12</Month>
<Day>30</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2021</Year>
<Month>1</Month>
<Day>6</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>epublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">33371468</ArticleId>
<ArticleId IdType="pii">ijms21249775</ArticleId>
<ArticleId IdType="doi">10.3390/ijms21249775</ArticleId>
<ArticleId IdType="pmc">PMC7767501</ArticleId>
</ArticleIdList>
<ReferenceList><Reference><Citation>Nature. 2020 Oct;586(7830):578-582</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32731258</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Indian Pediatr. 2020 May 15;57(5):407-410</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32291382</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>BMJ. 2020 Sep 4;370:m3379</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32887691</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 12;383(20):1920-1931</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32663912</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Antimicrob Agents. 2020 May;55(5):105960</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32251731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Rheumatol. 2020 Mar;16(3):155-166</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32034323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2019 Dec 12;381(24):2293-2303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31774950</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2013 Dec;11(12):836-48</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24217413</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Med Chem. 2020;27(27):4536-4541</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32297571</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Arch Pharm Res. 2020 Aug;43(8):765-772</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32740801</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Science. 2020 Apr 3;368(6486):14-16</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32241928</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 21;382(21):1969-1973</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Jul;20(7):816-826</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32325038</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hong Kong Med J. 2003 Dec;9(6):399-406</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14660806</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ther Clin Risk Manag. 2008 Oct;4(5):1023-33</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19209283</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2007 May 16;25(20):3980-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17382434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Microbiol. 2010 Jan;8(1):62-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">19966816</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Am J Health Syst Pharm. 2007 Aug 1;64(15):1593-602</Citation>
<ArticleIdList><ArticleId IdType="pubmed">17646561</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 22;395(10224):565-574</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32007145</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 May 7;382(19):1787-1799</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32187464</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Pharmacol. 2020 Dec;182:114225</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32956643</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Aug 15;396(10249):467-478</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32702298</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Clin Infect Dis. 2011 Aug 1;53(3):296-302</Citation>
<ArticleIdList><ArticleId IdType="pubmed">21765081</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Med Virol. 2020 Jul;92(7):740-746</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32227493</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Semin Immunol. 2013 Apr;25(2):152-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23735226</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biosci Trends. 2020 Mar 16;14(1):72-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32074550</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trials. 2018 Jan 30;19(1):81</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29382391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Ann Med. 2018 Mar;50(2):110-120</Citation>
<ArticleIdList><ArticleId IdType="pubmed">29172780</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Infect Dis. 2019 Jun 5;220(1):46-56</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30796818</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Aug 6;383(6):517-525</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32492293</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>J Microbiol Biotechnol. 2020 Mar 28;30(3):313-324</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32238757</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 May 16;395(10236):1569-1578</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32423584</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>iScience. 2020 Jul 24;23(7):101303</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32622261</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin Immunother. 2016 Dec;12(12):3103-3106</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27494532</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Feb;23(2):300-2</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23208422</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Thorax. 2004 Mar;59(3):252-6</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14985565</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Drug Discov. 2020 May;19(5):305-306</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32273591</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Mar 5;382(10):929-936</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32004427</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Open Forum Infect Dis. 2020 Jun 21;7(7):ofaa241</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32671131</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2020 Oct;586(7830):589-593</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32785213</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Pharmacol. 2020 Jun 19;11:937</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32636754</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Trop Med Rep. 2020 Mar 3;:1-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32219057</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA Netw Open. 2020 Apr 24;3(4):e208857</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32330277</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2020 Nov 17;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33217362</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Sep 26;396(10255):887-897</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32896291</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Dec 2;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33264556</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Drugs. 2003;63(8):769-802</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12662125</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Curr Opin Immunol. 2016 Aug;41:47-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27286566</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Microbiol. 2020 Apr;5(4):562-569</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32094589</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Rev Immunol. 2020 Oct;20(10):615-632</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32887954</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Discov. 2020 May 2;6:28</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32373347</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2020 Oct 20;:</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33082575</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>PLoS Pathog. 2020 May 14;16(5):e1008421</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32407364</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Oct 29;383(18):1701-1703</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32846056</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Antiviral Res. 2013 Nov;100(2):446-54</Citation>
<ArticleIdList><ArticleId IdType="pubmed">24084488</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trials. 2020 May 24;21(1):422</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32448345</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2016 Mar 17;531(7594):381-5</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26934220</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Dec 10;383(24):2320-2332</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32877576</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Microbiol. 2016 Jun;24(6):490-502</Citation>
<ArticleIdList><ArticleId IdType="pubmed">27012512</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virol J. 2005 Aug 22;2:69</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16115318</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Rev Panam Salud Publica. 2020 Mar 20;44:e40</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32256547</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell Res. 2013 Aug;23(8):986-93</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23835475</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Pharmacol Rep. 2020 Dec;72(6):1479-1508</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32889701</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Int J Mol Sci. 2020 May 27;21(11):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32471205</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2020 Feb 15;395(10223):497-506</Citation>
<ArticleIdList><ArticleId IdType="pubmed">31986264</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Brain Behav Immun. 2020 Jul;87:59-73</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32334062</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Virology. 2015 May;479-480:379-92</Citation>
<ArticleIdList><ArticleId IdType="pubmed">25864107</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Hum Vaccin. 2008 Jan-Feb;4(1):5-12</Citation>
<ArticleIdList><ArticleId IdType="pubmed">18438104</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>AAPS J. 2020 May 26;22(4):77</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32458279</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Viruses. 2020 Apr 14;12(4):</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32295237</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Immunol. 2018 Sep 19;9:1963</Citation>
<ArticleIdList><ArticleId IdType="pubmed">30283434</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Front Med. 2020 Apr;14(2):185-192</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32170560</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>JAMA. 2020 May 12;323(18):1824-1836</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32282022</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Biochem Biophys Res Commun. 2004 Oct 8;323(1):264-8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15351731</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccine. 2017 Aug 16;35(35 Pt A):4480-4485</Citation>
<ArticleIdList><ArticleId IdType="pubmed">28347504</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nature. 2004 Apr 1;428(6982):561-4</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15024391</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Respir Med. 2020 Nov;8(11):e85-e86</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32896274</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Nov 5;383(19):1813-1826</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32445440</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Vaccines (Basel). 2014 Jul 29;2(3):624-41</Citation>
<ArticleIdList><ArticleId IdType="pubmed">26344749</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Trends Microbiol. 2013 Oct;21(10):544-55</Citation>
<ArticleIdList><ArticleId IdType="pubmed">23770275</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Nat Med. 2005 Apr;11(4 Suppl):S16-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">15812483</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Cell. 2020 Apr 16;181(2):271-280.e8</Citation>
<ArticleIdList><ArticleId IdType="pubmed">32142651</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2003 Nov;3(11):722-7</Citation>
<ArticleIdList><ArticleId IdType="pubmed">14592603</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet. 2003 Apr 19;361(9366):1319-25</Citation>
<ArticleIdList><ArticleId IdType="pubmed">12711465</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>Lancet Infect Dis. 2006 Feb;6(2):67-9</Citation>
<ArticleIdList><ArticleId IdType="pubmed">16439323</ArticleId>
</ArticleIdList>
</Reference>
<Reference><Citation>N Engl J Med. 2020 Dec 17;383(25):2439-2450</Citation>
<ArticleIdList><ArticleId IdType="pubmed">33053279</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations><list><country><li>Corée du Sud</li>
</country>
<region><li>Région capitale de Séoul</li>
</region>
<settlement><li>Séoul</li>
</settlement>
<orgName><li>Université nationale de Séoul</li>
</orgName>
</list>
<tree><country name="Corée du Sud"><region name="Région capitale de Séoul"><name sortKey="Won, Jung Hyun" sort="Won, Jung Hyun" uniqKey="Won J" first="Jung-Hyun" last="Won">Jung-Hyun Won</name>
</region>
<name sortKey="Lee, Howard" sort="Lee, Howard" uniqKey="Lee H" first="Howard" last="Lee">Howard Lee</name>
<name sortKey="Lee, Howard" sort="Lee, Howard" uniqKey="Lee H" first="Howard" last="Lee">Howard Lee</name>
<name sortKey="Lee, Howard" sort="Lee, Howard" uniqKey="Lee H" first="Howard" last="Lee">Howard Lee</name>
<name sortKey="Lee, Howard" sort="Lee, Howard" uniqKey="Lee H" first="Howard" last="Lee">Howard Lee</name>
<name sortKey="Lee, Howard" sort="Lee, Howard" uniqKey="Lee H" first="Howard" last="Lee">Howard Lee</name>
<name sortKey="Won, Jung Hyun" sort="Won, Jung Hyun" uniqKey="Won J" first="Jung-Hyun" last="Won">Jung-Hyun Won</name>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000B49 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000B49 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    CovidChloroV1
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:33371468
   |texte=   The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:33371468" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a CovidChloroV1

This area was generated with Dilib version V0.6.38.
Data generation: Sat May 22 17:02:32 2021. Site generation: Sat May 22 17:06:52 2021

	Serveur d'exploration COVID et hydrochloroquine
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration COVID et hydrochloroquine

The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.

The Current Status of Drug Repositioning and Vaccine Developments for the COVID-19 Pandemic.

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki